^"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^Wu RL, Osman I, Wu XR, Lu ML, Zhang ZF, Liang FX, Hamza R, Scher H, Cordon-Cardo C, Sun TT (1998). "Uroplakin II gene is expressed in transitional cell carcinoma but not in bilharzial bladder squamous cell carcinoma: alternative pathways of bladder epithelial differentiation and tumor formation". Cancer Res. 58 (6): 1291–7. PMID9515818.
Lin JH, Wu XR, Kreibich G, Sun TT (1994). "Precursor sequence, processing, and urothelium-specific expression of a major 15-kDa protein subunit of asymmetric unit membrane". J. Biol. Chem. 269 (3): 1775–84. PMID7507484.
Wu XR, Lin JH, Walz T, et al. (1994). "Mammalian uroplakins. A group of highly conserved urothelial differentiation-related membrane proteins". J. Biol. Chem. 269 (18): 13716–24. PMID8175808.
Yuasa T, Yoshiki T, Isono T, et al. (1999). "Expression of transitional cell-specific genes, uroplakin Ia and II, in bladder cancer: detection of circulating cancer cells in the peripheral blood of metastatic patients". Int. J. Urol. 6 (6): 286–92. doi:10.1046/j.1442-2042.1999.00064.x. PMID10404304. S2CID43597402.
Li SM, Zhang ZT, Chan S, et al. (1999). "Detection of circulating uroplakin-positive cells in patients with transitional cell carcinoma of the bladder". J. Urol. 162 (3 Pt 1): 931–5. doi:10.1097/00005392-199909010-00093. PMID10458411.
Hirata H, Hisatomi H, Kawakita M, et al. (2004). "Genetic detection for hematogenous micrometastasis in patients with various types of malignant tumors using Uroplakin II derived primers in polymerase chain reaction". Oncol. Rep. 10 (4): 963–6. doi:10.3892/or.10.4.963. PMID12792753.